CLSD - Clearside Biomedical, Inc.
| Previous Close | 1.2600 |
| Open | 1.2800 |
| Bid | 1.31 x 800 |
| Ask | 1.32 x 1300 |
| Day's Range | 1.2500 - 1.3400 |
| 52 Week Range | 1.2500 - 15.3290 |
| Volume | 193,207 |
| Avg. Volume | 438,400 |
| Market Cap | 42.272M |
| Beta (3Y Monthly) | -4.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.67 |
| Earnings Date | Mar 12, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.86 |
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of CLSD earnings conference call or presentation 8-Nov-18 1:30pm GMT
Q3 2018 Clearside Biomedical Inc Earnings Call
- GlobeNewswire•20 days ago
Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•last month
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended September 30, 2018 and provided an update on its development programs.
- GlobeNewswire•last month
Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
ALPHARETTA, Ga., Nov. 07, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Teladoc Health and Clearside
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / Shares of Teladoc Health were in the red on Monday after its CFO and COO sold off a big stake of his shares. Shares of Clearside Biomedical were also in the red on disappointing trial results. One was that the company's COO and CFO, Mark Hirschhorn had sold over $700,000 worth of shares last Friday, which amounted to over 81% of his stake in the company.
- GlobeNewswire•last month
Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its third quarter 2018 financial results will be released at approximately 7:00 a.m. ET on Thursday, November 8, 2018. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss its financial results and provide a general business and strategic review.
- Insider Monkey•last month
Major Stock Movers: Inuvo, Clearside Biomedical, Cirrus Logic, and More
It’s Monday and oil futures are relatively stable despite the news that the U.S. is beginning to impose sanctions on Iran again. Among the stocks making substantial waves today include Inuvo Inc. (NYSE:INUV), Clearside Biomedical Inc. (NASDAQ:CLSD), Sysco Corporation (NYSE:SYY), STMicroelectronics N.V. (NYSE:STM), and Cirrus Logic Inc. (NASDAQ:CRUS). Let’s dig deeper into why each stock moved. In the financial world […]
- GlobeNewswire•last month
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
- Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 - - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week Topline Data -.
- GlobeNewswire•2 months ago
Presentation of Additional Analyses of Clearside’s PEACHTREE Clinical Trial Data Further Supports Potential of XIPERE™ in Treating Uveitic Macular Edema
ALPHARETTA, Ga., Oct. 29, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire•2 months ago
Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas A. Ciulla, M.D., M.B.A. to the position of Chief Medical Officer. Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research laboratory at Indiana University School of Medicine, the largest U.S. medical school. Today, he remains a volunteer Clinical Professor of Ophthalmology at the university and also serves on the Board of Directors of Midwest Eye Institute. Dr. Ciulla is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and the American Academy of Ophthalmology.
- GlobeNewswire•2 months ago
CLEARSIDE, XIPERE™ and PEACHTREE to be Front and Center at AAO 2018
ALPHARETTA, Ga., Oct. 22, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Positive PEACHTREE Data to be Highlighted at EURETINA 2018
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann, MD, Uveitis Specialist at Maccabi Health Services, Tel Aviv, Israel and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming European Society of Retina Specialists (EURETINA) Congress 2018 in Vienna, Austria.
- Simply Wall St.•3 months ago
What Investors Should Know About Clearside Biomedical Inc’s (NASDAQ:CLSD) Financial Strength
Clearside Biomedical Inc (NASDAQ:CLSD) is a small-cap stock with a market capitalization of US$210.7m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
- ACCESSWIRE•4 months ago
Clearside Biomedical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Clearside Biomedical, Inc. (NASDAQ: CLSD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern ...
